Abstract
Since 1989, about 570 different p53 mutations have been identified in more than 8000 human cancers. A database of these mutations was initiated by M. Hollstein and C. C. Harris in 1990. This database originally consisted of a list of somatic point mutations in the p 53 gene of human tumors and cell lines, compiled from the published literature and made available in a standard electronic form. The database is maintained at the International Agency for Research on Cancer (IARC) and updated versions are released twice a year (January and July). The current version (July 1997) contains records on 6800 published mutations and will surpass the 8000 mark in the January 1998 release. The database now contains information on somatic and germline mutations in a new format to facilitate data retrieval. In addition, new tools are constructed to improve data analysis, such as a Mutation Viewer Java applet developed at the European Bioinformatics Institute (EBI) to visualise the location and impact of mutations on p53 protein structure. The database is available in different electronic formats at IARC (http://www.iarc. fr/p53/homepage.htm ) or from the EBI server (http://www.ebi.ac.uk ). The IARC p53 website also provides reports on database analysis and links with other p53 sites as well as with related databases. In this report, we describe the criteria for inclusion of data, the revised format and the new visualisation tools. We also briefly discuss the relevance of p 53 mutations to clinical and biological questions.
Full Text
The Full Text of this article is available as a PDF (250.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aas T., Børresen A. L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J. E., Akslen L. A., Lønning P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996 Jul;2(7):811–814. doi: 10.1038/nm0796-811. [DOI] [PubMed] [Google Scholar]
- Brennan J. A., Boyle J. O., Koch W. M., Goodman S. N., Hruban R. H., Eby Y. J., Couch M. J., Forastiere A. A., Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995 Mar 16;332(11):712–717. doi: 10.1056/NEJM199503163321104. [DOI] [PubMed] [Google Scholar]
- Béroud C., Verdier F., Soussi T. p53 gene mutation: software and database. Nucleic Acids Res. 1996 Jan 1;24(1):147–150. doi: 10.1093/nar/24.1.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cariello N. F., Douglas G. R., Gorelick N. J., Hart D. W., Wilson J. D., Soussi T. Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents. Nucleic Acids Res. 1998 Jan 1;26(1):198–199. doi: 10.1093/nar/26.1.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994 Jul 15;265(5170):346–355. doi: 10.1126/science.8023157. [DOI] [PubMed] [Google Scholar]
- Denissenko M. F., Pao A., Tang M., Pfeifer G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 1996 Oct 18;274(5286):430–432. doi: 10.1126/science.274.5286.430. [DOI] [PubMed] [Google Scholar]
- Dogliotti E. Mutational spectra: from model systems to cancer-related genes. Carcinogenesis. 1996 Oct;17(10):2113–2118. doi: 10.1093/carcin/17.10.2113. [DOI] [PubMed] [Google Scholar]
- Etzold T., Argos P. SRS--an indexing and retrieval tool for flat file data libraries. Comput Appl Biosci. 1993 Feb;9(1):49–57. doi: 10.1093/bioinformatics/9.1.49. [DOI] [PubMed] [Google Scholar]
- Forrester K., Lupold S. E., Ott V. L., Chay C. H., Band V., Wang X. W., Harris C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 1995 Jun 1;10(11):2103–2111. [PubMed] [Google Scholar]
- Goh H. S., Yao J., Smith D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995 Nov 15;55(22):5217–5221. [PubMed] [Google Scholar]
- Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
- Harris C. C. The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer. 1996 Feb;73(3):261–269. doi: 10.1038/bjc.1996.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harris C. C. p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. Carcinogenesis. 1996 Jun;17(6):1187–1198. doi: 10.1093/carcin/17.6.1187. [DOI] [PubMed] [Google Scholar]
- Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed] [Google Scholar]
- Kleihues P., Schäuble B., zur Hausen A., Estève J., Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997 Jan;150(1):1–13. [PMC free article] [PubMed] [Google Scholar]
- Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1;10(9):1054–1072. doi: 10.1101/gad.10.9.1054. [DOI] [PubMed] [Google Scholar]
- Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., Monden Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol. 1996 Jan;61(1):20–26. doi: 10.1002/(SICI)1096-9098(199601)61:1<20::AID-JSO6>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
- Lehman T. A., Harris C. C. Mutational spectra of protooncogenes and tumour suppressor genes: clues in predicting cancer etiology. IARC Sci Publ. 1994;(125):399–412. [PubMed] [Google Scholar]
- Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb 7;88(3):323–331. doi: 10.1016/s0092-8674(00)81871-1. [DOI] [PubMed] [Google Scholar]
- Montesano R., Hollstein M., Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996 Jun 21;69(3):225–235. doi: 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
- Nakazawa H., English D., Randell P. L., Nakazawa K., Martel N., Armstrong B. K., Yamasaki H. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):360–364. doi: 10.1073/pnas.91.1.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994 Aug 1;13(15):3496–3504. doi: 10.1002/j.1460-2075.1994.tb06656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sidransky D., Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 1996;47:285–301. doi: 10.1146/annurev.med.47.1.285. [DOI] [PubMed] [Google Scholar]
- Taylor J. A., Li Y., He M., Mason T., Mettlin C., Vogler W. J., Maygarden S., Liu E. p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res. 1996 Jan 15;56(2):294–298. [PubMed] [Google Scholar]